Physician profile
Dulce C Cabrera
NPI 1952407025
$513.44
in general payments reported to CMS, 2019-2025
12 companies · $25.36 in 2025
The $25.36 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $182 · 2023: $29.90 · 2024: $30.51 · 2025: $25.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $85.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $85.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $114.93 | 2019-2020 | |
| Pfizer INC. | $100.01 | 2019-2020 | |
| Hologic Sales and Service, LLC | $55.87 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.37 | 2020 | |
| Celgene Corporation | $41.49 | 2019 | |
| Abbvie INC. | $29.90 | 2023 | Vraylar |
| Aclaris Therapeutics, INC. | $24.18 | 2019 | |
| Almirall LLC | $22.26 | 2019 | |
| Vyne Pharmaceuticals INC. | $20.59 | 2020 | |
| Mayne Pharma Commercial LLC | $20.23 | 2019 | |
| Merck Sharp & Dohme LLC | $17.61 | 2019 | |
| Glenmark Therapeutics INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dulce Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.